Targeting IL-17A to manage immunotherapy-induced toxicity in melanoma  

作　　者：Kai Huang 

机构地区：[1]Department of Medical Oncology,Qilu Hospital of Shandong University,Jinan,Shandong,P.R.China [2]Department of Cancer Biology,Perelman School of Medicine,University of Pennsylvania,Philadelphia,Pennsylvania,USA

出　　处：《Cancer Communications》2025年第1期56-57,共2页癌症通讯(英文)

基　　金：National Natural Science Foundation of China,Grant/Award Number:82103209;Taishan Schorlar of Shandong Province,Grant/Award Number:tsqn202103174。

摘　　要：The landscape of cancer treatment has been dramatically transformed by the advent of immune checkpoint inhibitors(ICIs),particularly in the management of advanced melanoma.However,despite their revolutionary success,the use of ICIs is often complicated by immunerelated adverse events(irAEs),which can range from mild symptoms to severe,life-threatening conditions.Understanding the underlying mechanisms of these toxicities is crucial to enhancing the safety and effectiveness of immunotherapy[1].

关 键 词：MELANOMA IMMUNOTHERAPY IMMUNE 

分 类 号：R73[医药卫生—肿瘤]